High & Low Dose Oral Peanut Immunotherapy

Status Recruiting

Clinical Trial Summary

In this trial the investigators aim to assess the effectiveness and safety of oral immunotherapy with peanut protein in high and low dose (300mg versus 150mg) in children with peanuts allergy.

Clinical Trial Description

Peanut allergy is a significant clinical problem. Food immunotherapy provides the latest approach to managing food allergy. Oral immunotherapy is considered as the most effective and safe, according to current research. What is more, this type of therapy is easily available and can be continued at patient's home. Obtaining and maintenance of tolerance to the allergic food is the main goal of this procedure. The study will include children with peanut allergy, confirmed during open oral food challenge (OOFC) with peanut protein. First OOFC will be performed before immunotherapy, second one at the end of procedure. Participants will be randomly assigned to two groups. During the maintenance phase, the first group will receive low dose of peanut protein, which amounts 150mg, the second will get high dose, which is 300 mg of peanut protein. Oral immunotherapy with low and high dose of peanut protein in children randomly assigned to two groups (1:1). In the following phase, every two weeks the dose of ground roasted peanut will be increased and applied to a child during hospitalization (1-day procedure). Precondition to increase of dose is good tolerance of previous portion of peanut. The maximum time frame for this phase is 14 months. After achieving tolerance, immunotherapy will be continued for 2 months in maintenance phase, with dose 150mg or 300 mg peanut protein, depending on a study group. The dosage increasing phase will last maximally 14 months. If patients achieves the maintenance dose earlier, this period may be shorter. Maintenance dose is determined by random patients' assignment to one from study's group and amounts 150mg or 300 mg of peanut protein, respectively. The duration of the maintenance phase is 8 weeks (+/-2 weeks). After 2 months (8 weeks +/-2 weeks) of maintenance dose the final OOFC and evaluation of tolerance of peanut protein will be performed. Confirmation of the total desensitization of peanut is the tolerance of a single dose of 4500 mg peanut protein. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04415593
Study type	Interventional
Source	Medical University of Warsaw
Contact	Klementyna Lyzwa, MD
Phone	+488607153221
Email	klementyna.jozwik@gmail.com
Status	Recruiting
Phase	N/A
Start date	September 1, 2020
Completion date	May 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05667610` - Immune-supportive Diet and Gut Permeability in Allergic Children	N/A
Recruiting	`NCT05440643` - Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy	Phase 1
Terminated	`NCT03849079` - Validation of the HYPONUT Product	N/A
Completed	`NCT02979600` - Clinical and Biological Efficacy of Peanut Oral Immunotherapy	N/A
Completed	`NCT01955109` - Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children	Phase 2
Completed	`NCT01950533` - The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
Active, not recruiting	`NCT04511494` - Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT	N/A
Active, not recruiting	`NCT04887441` - Allergology: Information, Data and Knowledge Organization
Active, not recruiting	`NCT04881773` - Oral Low Doses Tolerance INduction Study for Peanuts
Completed	`NCT03682770` - Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)	Phase 2
Terminated	`NCT03703791` - Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents	Phase 3
Completed	`NCT02916446` - Safety Study of Viaskin Peanut to Treat Peanut Allergy	Phase 3
Active, not recruiting	`NCT02402231` - Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy	Phase 2
Completed	`NCT03337542` - AR101 Real-World Open-Label Extension Study	Phase 3
Recruiting	`NCT05476497` - Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects	Phase 1
Completed	`NCT03648320` - The Grown Up Peanut Immunotherapy Study	N/A
Completed	`NCT03292484` - Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)	Phase 3
Completed	`NCT03852342` - Reactive Doses and Times During Oral Food Challenge to Peanut
Recruiting	`NCT05138757` - Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy	Phase 1/Phase 2
Completed	`NCT03352726` - A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms